1. Home
  2. CRNX vs SNX Comparison

CRNX vs SNX Comparison

Compare CRNX & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.25

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo TD SYNNEX Corporation

SNX

TD SYNNEX Corporation

HOLD

Current Price

$159.40

Market Cap

12.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
SNX
Founded
2008
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
12.7B
IPO Year
2018
2003

Fundamental Metrics

Financial Performance
Metric
CRNX
SNX
Price
$36.25
$159.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
10
Target Price
$74.78
$168.80
AVG Volume (30 Days)
1.0M
419.0K
Earning Date
05-07-2026
03-31-2026
Dividend Yield
N/A
1.17%
EPS Growth
N/A
25.16
EPS
N/A
9.95
Revenue
$1,039,000.00
$20,053,764,000.00
Revenue This Year
$722.66
$5.01
Revenue Next Year
$183.79
$4.18
P/E Ratio
N/A
$16.45
Revenue Growth
N/A
17.65
52 Week Low
$24.10
$92.23
52 Week High
$57.99
$175.56

Technical Indicators

Market Signals
Indicator
CRNX
SNX
Relative Strength Index (RSI) 37.03 52.86
Support Level $33.23 $144.64
Resistance Level $37.23 $159.61
Average True Range (ATR) 1.49 4.34
MACD 0.22 0.83
Stochastic Oscillator 53.29 60.01

Price Performance

Historical Comparison
CRNX
SNX

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About SNX TD SYNNEX Corporation

TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.

Share on Social Networks: